Table 2.
Antidepressants exposure of the study population, divided by antidepressant category. Values are numbers (percentages) unless stated otherwise
| Antidepressants exposure | Study population N = 673 177 (%) | |
|---|---|---|
| TCAs | 46 580 (6.9) | |
| Amitriptyline | 21 528 (3.2) | |
| Clomipramine | 636 (0.1) | |
| Dosulepin | 16 187 (2.4) | |
| Doxepin | 304 (0.1) | |
| Imipramine | 802 (0.1) | |
| Lofepramine | 6257 (0.9) | |
| Maprotiline | 14 (0.0) | |
| Mianserin | 65 (0.0) | |
| Nortriptyline | 408 (0.1) | |
| Trimipramine | 378 (0.1) | |
| SSRIs | 576 936 (85.7) | |
| Citalopram | 242 930 (36.1) | |
| Escitalopram | 19 026 (2.8) | |
| Fluoxetine | 150 274 (22.3) | |
| Fluvoxamine | 153 (0.0) | |
| Paroxetine | 28 613 (4.3) | |
| Sertraline | 135 940 (20.2) | |
| MAOIs | 85 (0.0) | |
| Moclobemide | 66 (0.0) | |
| Phenelzine | 10 (0.0) | |
| Other antidepressants | 49 576 (7.4) | |
| Agomelatine | 30 (0.0) | |
| Duloxetine | 1213 (0.2) | |
| Mirtazapine | 39 253 (5.8) | |
| Nefazodone | 238 (0.0) | |
| Reboxetine | 337 (0.1) | |
| Trazodone | 3835 (0.6) | |
| Venlafaxine | 4623 (0.7) | |
| Vortioxetine | 45 (0.0) | |
| Othersa | 12 (0.0) |
MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
a.
Amoxapine, isocarboaxazid, tranylcypromine and tryptophan had fewer than 5 participants and were therefore excluded from the table to comply with QResearch data management guidelines.